tirzepatide cardiovascular trial π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT found that was noninferior to dulaglutide for major events (12.2% vs 13.1%; HR 0.92). What It's important to study the
Pay in 4 interest-free payments of $5.32 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 16 - Aug 21





























